Inhibitor development and mortality in non-severe hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 7, 2015, Pages 1217-1225

  Eckhardt, C L ^a,j   Loomans, J I ^a   van Velzen, A S ^a,j   Peters, M ^a,j   Mauser Bunschoten, E P ^b   Schwaab, R ^c   Mazzucconi, M G ^d   Tagliaferri, A ^e   Siegmund, B ^f   Reitter Pfoertner, S E ^g   van der Bom, J G ^h,i   Fijnvandraat, K ^a,j   Kamphuisen, P W ^j   Peerlinck, K ^k   Oldenburg, J ^c   Santagostino, E ^l   Astermark, J ^m   Streefkerk, N ^aa   Loomans, J L ^aa   van Eijkelenburg, A ^aa   Jansen, A J ^aa   Kruijt, C C ^aa   van Tienoven, B ^aa   van Baar, A C G ^aa   Corten, I W ^aa   Meijer, K ⁿ   Nijziel, M R ^o   Dors, N ^p   Hamulyak, K ^q   Beckers, E ^q   Brons, P P ^r   Laros van Gorkom, B A P ^r   van Heerde, W L ^r   Leebeek, F ^s   Kruip, M ^s   Cnossen, M H ^s   Mauser Bunschoten, E ^t   Fischer, K ^t   Smiers, F J ⁱ   Hermans, C ^u   Klamroth, R ^v   Escuriola Ettingshausen, C ^w   Konigs C ^w   Petrini, P ^x   Holmstrom M ^x   Makipernaa A ^y   Male, C ^g   Pabinger, I ^g   Keenan, R D ^z   Liesner, R ^aa   Khair, K ^aa   Yee, T T ^ab   Hart, D P ^ac   Rangarajan, S ^ad   Mitchell, M ^ad   Thompson, G ^ad   Haya, S ^ae   Moret, A ^ae   Cid, A R ^ae   Jimenez Yuste, V ^af   Mancuso, M E ^l   Mazzuconni, M G ^d   Santoro, C ^d   Morfini, M ^ag   Castaman, G ^ah   Schinco, P ^ai   Rivolta, G F ^e   Platokouki, H ^aj   McRae, S ^ak   more..

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f Raphaels Klinik Munster GmbH   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h SANQUIN RESEARCH   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF LEUVEN   (Belgium)

^l UNIVERSITY OF MILAN   (Italy)

^m LUND UNIVERSITY HOSPITAL   (Sweden)

ⁿ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^o MÁXIMA MEDICAL CENTER   (Netherlands)

^p CATHARINA HOSPITAL   (Netherlands)

^q MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^r RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^s ERASMUS MEDICAL CENTER   (Netherlands)

^t UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^u CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^v VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^w UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^x KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^y UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^z ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^aa JW Goethe University Hospital ^*

^ab ROYAL FREE HOSPITAL   (United Kingdom)

^ac ROYAL LONDON HOSPITAL   (United Kingdom)

^ad GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^ae HOSPITAL UNIVERSITARIO LA FE   (Spain)

^af HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^ag CAREGGI UNIVERSITY HOSPITAL   (Italy)

^ah SAN BORTOLO HOSPITAL   (Italy)

^ai MOLINETTE HOSPITAL   (Italy)

^aj AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^ak ROYAL ADELAIDE HOSPITAL   (Australia)

more..

Author keywords

Cause of death; Hemophilia A; Hemorrhage; Mortality; Neutralizing antibodies

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY;

ADULT; AGE; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CHILD; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TIME OF DEATH; ADOLESCENT; AUSTRALIA; BLOOD; CLINICAL TRIAL; EUROPE; HEMORRHAGE; IMMUNOLOGY; MULTICENTER STUDY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, NEUTRALIZING; AUSTRALIA; AUTOANTIBODIES; BIOMARKERS; CAUSE OF DEATH; CHILD; EUROPE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 84935756053     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12990     Document Type: Article

References (26)

1. Fijnvandraat K, Cnossen MH, Leebeek FW, Peters M. Diagnosis and management of haemophilia. BMJ 2012; 344: e2707.
2. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27: 179-84.
3. Castaman G. Desmopressin for the treatment of haemophilia. Haemophilia 2008; 14(Suppl 1): 15-20.
4. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10(Suppl 2): 22-9.
5. Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, Cnossen MH, Dors N, Escuriola-Ettingshausen C, Hamulyak K, Hart DP, Hay CR, Haya S, van Heerde WL, Hermans C, Holmström M, Jimenez-Yuste V, Keenan RD, Klamroth R, Laros-van Gorkom BA, etal. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954-62.
6. Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8: 421-32.
7. Hay CR, Ludlam CA, Colvin BT, Hill FG, Preston FE, Wasseem N, Bagnall R, Peake IR, Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
8. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-6.
9. Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815-25.
10. Tagliaferri A, Rivolta GF, Iorio A, Oliovecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M, Italian Association of Hemophilia Centers, Ciavarella N, Scaraggi A, Valdrè L, Tagariello G, Radossi P, Muleo G, Iannaccaro PG, Biasoli C, Vincenzi D, Serino ML, etal. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
11. Eckhardt CL, Menke LA, van Ommen CH, van der Lee JH, Geskus RB, Kamphuisen PW, Peters M, Fijnvandraat K. Intensive peri-operative use of factor VIII and the Arg593 -> Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A. J Thromb Haemost 2009; 7: 930-7.
12. Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, Hill FG, Hay CR, UK Haemophilia Centre Doctors' Organisation. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
13. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71.
14. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, De Goede-Bolder A, Heijnen L, Smit C, Zwart-van Rijkom JE, Willemse J, Rosendaal FR. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004; 104: 3494-500.
15. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
16. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
17. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. http://apps.who.int/classifications/icd10. Accessed 13 January 2014.
18. van der Bom JG, ter Avest P, van den Berg HM, Psaty BM, Weiss NS. Assessment of incidence of inhibitors in patients with haemophilia. Haemophilia 2009; 15: 707-11.
19. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new who standard. 2001 http://www.who.int/healthinfo/paper31.pdf. Accessed 2 February 2014.
20. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. http://www.OpenEpi.com. Accessed 13 January 2014.
21. Rothman KJ, Boice JD. Epidemiologic Analysis with a Programmable Calculator: NIH publication, no. 79-1649. Washington, DC: U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, 1979.
22. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-33.
23. Mauser-Bunschoten EP, Fransen van de Putte DE, Schutgens RE. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 2009; 15: 853-63.
24. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
25. Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K. Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia 2012; 18: 263-7.
26. Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost 2010; 8: 2224-31.